[AUPH] Aurinia Pharmaceuticals Inc


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 99.78 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.18 Change: 0.03 (1.4%)
Ext. hours: 2.19 Change: 0.01 (0.46%)

chart AUPH

Refresh chart

Strongest Trends Summary For AUPH

AUPH is in the long-term up 90% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Fundamental Ratios
Shares Outstanding32.29 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week7.64 Low 52 week4.53 Last close7.2 Last change16.32%
RSI57.14 Average true range0.31 Beta0.79 Volume1.13 M
Simple moving average 20 days11.65% Simple moving average 50 days10.47% Simple moving average 200 days23.03%
Performance Data
Performance Week8.93% Performance Month13.92% Performance Quart35.85% Performance Half27.43%
Performance Year44.58% Performance Year-to-date5.57% Volatility daily4.33% Volatility weekly9.69%
Volatility monthly19.86% Volatility yearly68.8% Relative Volume859.31% Average Volume1.02 M
New High New Low


2019-06-21 07:59:00 | ILJIN Chairman Issues Open Letter to Aurinia Shareholders

2019-06-21 06:30:00 | Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline

2019-06-20 08:00:00 | As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential

2019-06-19 06:30:00 | Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees

2019-06-12 08:00:00 | ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts

2019-06-10 14:58:00 | ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information

2019-06-07 08:00:00 | Aurinia Issues Letter to Shareholders

2019-06-04 16:05:00 | Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

2019-06-03 15:09:00 | Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders

2019-05-31 08:30:00 | Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders

2019-05-17 16:02:00 | Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

2019-05-14 17:15:09 | Aurinia Pharmaceuticals AUPH Reports Q1 Loss

2019-05-14 16:10:32 | Aurinia: 1Q Earnings Snapshot

2019-05-14 16:02:00 | Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights

2019-05-10 07:00:00 | Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis

2019-05-02 10:33:02 | Aurinia Pharmaceuticals AUPH May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-30 06:05:00 | Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen

2019-04-24 16:05:00 | Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

2019-04-22 14:41:13 | Former MedImmune president Greenleaf tapped to lead Canadian biotech

2019-04-11 16:30:00 | Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board

2019-04-10 08:46:12 | Implied Volatility Surging for Aurinia Pharmaceuticals AUPH Stock Options

2019-03-19 22:14:56 | Aurinia Pharmaceuticals Inc AUPH Q4 2018 Earnings Conference Call Transcript

2019-03-19 16:14:33 | Aurinia: 4Q Earnings Snapshot

2019-03-19 16:02:00 | Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

2019-03-19 14:30:00 | Aurinia Pharmaceuticals Inc. to Host Earnings Call

2019-03-14 07:00:00 | Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

2019-03-12 10:30:02 | Analysts Estimate Aurinia Pharmaceuticals AUPH to Report a Decline in Earnings: What to Look Out for

2019-03-07 16:05:00 | Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

2019-02-27 11:39:23 | After Patent News, Aurinia Pharmaceuticals Still Has More to Prove

2019-02-27 06:30:00 | Aurinia Closes At-The-Market Facility

2019-02-26 13:28:31 | Big Pharma faces the Senate in drug price hearings

2019-02-25 16:16:00 | Here's Why Aurinia Pharmaceuticals' Stock Jumped Today

2019-02-25 07:00:00 | Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

2019-02-20 16:01:00 | Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

2019-01-30 14:33:21 | Is Aurinia Pharmaceuticals a Buy?

2019-01-30 08:10:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth

2019-01-22 09:09:32 | Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial

2019-01-22 07:00:00 | Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

2019-01-21 16:49:00 | Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome

2019-01-21 08:45:01 | Do Options Traders Know Something About Aurinia Pharmaceuticals AUPH Stock We Don't?

2019-01-16 08:20:00 | My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout

2018-12-20 12:10:00 | 4 Pharma Stocks Getting a Boost on Thursday 12/20/18

2018-12-19 08:00:00 | Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

2018-11-30 17:18:00 | Aurinia Establishes at-the-Market Facility

2018-11-27 08:00:00 | Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-09 07:00:00 | Aurinia to Participate in November Investor Conferences

2018-11-08 17:45:10 | Aurinia Pharmaceuticals AUPH Reports Q3 Loss, Tops Revenue Estimates

2018-11-08 16:39:29 | Aurinia: 3Q Earnings Snapshot

2018-11-08 16:02:00 | Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development

2018-10-25 07:00:00 | Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018